Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action-Reference-Cited by-同舟云学术

Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action

Published:2017-11 Issue: Volume:277 Page:195-203
ISSN:0009-2797
Container-title:Chemico-Biological Interactions
language:en
Short-container-title:Chemico-Biological Interactions

Author:

Arafa Nadia M.S.,Ali Elham H.A.,Hassan Mohamed Kamel

Funder

Department of physiology, NODCAR, Egypt

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference40 articles.

1. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2;Kanwal;Anal. Biochem.,2012

2. 5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes;Ohtake;Bioorg. Med. Chem.,2011

3. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats;Yokono;Eur. J. Pharmacol.,2014

4. Effect of canagliflozin or metformin on metabolic disorders in obese diabetic rats;Marie;Afr. J. Pharm. Pharmacol.,2015

5. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease-diabetes type 2 linkage via an Enzoinformatics Study;Rizvi;CNS Neurological Disorders-Drug Targets (Formerly Curr. Drug Targets-CNS Neurological Disord).,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease;Biomedicines;2024-01-03

2. Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?;Pharmacological Research;2024-01

3. Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease;Pharmaceuticals;2023-11-16

4. Neuroprotective potential of gliflozins;Diabetes mellitus;2023-11-16

5. Life-threatening coronary vasospasm in patients with type 2 diabetes with SGLT2 inhibitor-induced euglycemic ketoacidosis: a report of two consecutive cases;Diabetology International;2023-11-13